[Skip to Content]
Sign In
Individual Sign In
Create an Account
Institutional Sign In
OpenAthens Shibboleth
[Skip to Content Landing]

July 2019 - April 2016

Decade

Year

Issue

September 2016, Vol 1, No. 6, Pages 625-738

In This Issue of JAMA Cardiology

Highlights

Abstract Full Text
free access
JAMA Cardiol. 2016;1(6):625. doi:10.1001/jamacardio.2015.0032
Original Investigation

Rates of Invasive Management of Cardiogenic Shock in New York Before and After Exclusion From Public Reporting

Abstract Full Text
free access has audio
JAMA Cardiol. 2016;1(6):640-647. doi:10.1001/jamacardio.2016.0785

This study reports on rates of invasive treatment for cardiogenic shock before and after exclusion from public reporting in New York was implemented and compares these findings with rates in other states without public reporting.

Treatment and Outcomes of Acute Myocardial Infarction Complicated by Shock After Public Reporting Policy Changes in New York

Abstract Full Text
free access
JAMA Cardiol. 2016;1(6):648-654. doi:10.1001/jamacardio.2016.1806

This study examines the effects of a public reporting exclusion policy on the change on rates of revascularization and mortality for patients with acute myocardial infarction complicated by cardiogenic shock in New York vs comparative states without public reporting.

Comparing Inverse Probability of Treatment Weighting and Instrumental Variable Methods for the Evaluation of Adenosine Diphosphate Receptor Inhibitors After Percutaneous Coronary Intervention

Abstract Full Text
free access
JAMA Cardiol. 2016;1(6):655-665. doi:10.1001/jamacardio.2016.1783

This study investigates changes in the findings of TRANSLATE-ACS, a cohort study comparing the safety and efficacy of prasugrel vs clopidogrel after PCI, when the study data are reanalyzed using instrumental variables vs the investigators’ original inverse probability treatment weighting approach.

Cost-effectiveness Analysis of Sacubitril/Valsartan vs Enalapril in Patients With Heart Failure and Reduced Ejection Fraction

Abstract Full Text
free access
JAMA Cardiol. 2016;1(6):666-672. doi:10.1001/jamacardio.2016.1747

This 2-state Markov model estimates the cost-effectiveness of sacubitril/valsartan vs enalapril to treat patients with heart failure.

Apixaban 5 mg Twice Daily and Clinical Outcomes in Patients With Atrial Fibrillation and Advanced Age, Low Body Weight, or High Creatinine: A Secondary Analysis of a Randomized Clinical Trial

Abstract Full Text
free access
JAMA Cardiol. 2016;1(6):673-681. doi:10.1001/jamacardio.2016.1829

This secondary analysis of a randomized clinical trial assesses the effects of apixaban doses in patients with atrial fibrillation and 1 dose-reduction criterion.

Practice Patterns and Outcomes Associated With Use of Anticoagulation Among Patients With Atrial Fibrillation During Sepsis

Abstract Full Text
free access
JAMA Cardiol. 2016;1(6):682-690. doi:10.1001/jamacardio.2016.2181

This cohort study uses administrative claims data to describe use of anticoagulation for atrial fibrillation during sepsis and to compare risk of stroke and bleeding with vs without anticoagulation.

Association of Lipid Fractions With Risks for Coronary Artery Disease and Diabetes

Abstract Full Text
free access
JAMA Cardiol. 2016;1(6):692-699. doi:10.1001/jamacardio.2016.1884

This study uses published GWAS data and mendelian randomization analysis to compare measures of association between lipid fractions (LDL, HDL, triglycerides) and coronary artery disease vs diabetes.

Population Effect of Differences in Cholesterol Guidelines in Eastern Europe and the United States

Abstract Full Text
free access
JAMA Cardiol. 2016;1(6):700-707. doi:10.1001/jamacardio.2016.1585

This analysis of 2 population-based surveys examines the differences in recommendations regarding statin therapy between the American College of Cardiology/American Heart Association guidelines for the management of cholesterol and the European Society of Cardiology/European Atherosclerosis Society guidelines.

Brief Report

Comparison of ACC/AHA and ESC Guideline Recommendations Following Trial Evidence for Statin Use in Primary Prevention of Cardiovascular Disease: Results From the Population-Based Rotterdam Study

Abstract Full Text
free access
JAMA Cardiol. 2016;1(6):708-713. doi:10.1001/jamacardio.2016.1577

This study evaluates the overlap between the American College of Cardiology/American Heart Association and European Society of Cardiology guideline recommendations and available evidence from randomized clinical trials for statin use in primary prevention of cardiovascular disease.

Potential Mortality Reduction With Optimal Implementation of Angiotensin Receptor Neprilysin Inhibitor Therapy in Heart Failure

Abstract Full Text
free access
JAMA Cardiol. 2016;1(6):714-717. doi:10.1001/jamacardio.2016.1724

This study quantifies the projected gains for deaths prevented or postponed with comprehensive implementation of angiotensin receptor neprilysin inhibition therapy for patients in the United States with heart failure and reduced ejection fraction.

Research Letter

Implementation of the Affordable Care Act and Solid-Organ Transplantation Listings in the United States

Abstract Full Text
free access
JAMA Cardiol. 2016;1(6):737-738. doi:10.1001/jamacardio.2016.2067

This study uses UNOS data to compare listings for heart, liver, and kidney transplantation before and after implementation of the Affordable Care Act in states that did or did not adopt Medicaid expansion.

Viewpoint

Antiplatelet Therapy for Long-term Secondary Prevention After Myocardial Infarction

Abstract Full Text
has audio
JAMA Cardiol. 2016;1(6):627-628. doi:10.1001/jamacardio.2016.2110

This Viewpoint discusses several large trials that have evaluated the efficacy and safety of more intensive antiplatelet strategies for long-term prevention of major adverse cardiovascular events.

Extended Dual Antiplatelet Therapy in Patients With Prior Myocardial Infarction

Abstract Full Text
JAMA Cardiol. 2016;1(6):629-630. doi:10.1001/jamacardio.2016.2252

This Viewpoint argues against extending dual antiplatelet therapy for more than 1 year after myocardial infarction based on a subgroup analysis of PEGASUS-TIMI 54 trial data.

From the Heart

Writing Out Loud: To Computers, Patients, and Burnout, 2016

Abstract Full Text
JAMA Cardiol. 2016;1(6):639. doi:10.1001/jamacardio.2016.2073
Editorial

Disentangling the Causal Association of Plasma Lipid Traits and Type 2 Diabetes Using Human Genetics

Abstract Full Text
JAMA Cardiol. 2016;1(6):631-633. doi:10.1001/jamacardio.2016.2298

Randomization—There Is No Substitute

Abstract Full Text
JAMA Cardiol. 2016;1(6):633-635. doi:10.1001/jamacardio.2016.1792

Appropriate Apixaban Dosing: Prescribers Take Note

Abstract Full Text
JAMA Cardiol. 2016;1(6):635-636. doi:10.1001/jamacardio.2016.1841

The Complicated Calculus of Publicly Reporting Mortality After Percutaneous Coronary Intervention

Abstract Full Text
JAMA Cardiol. 2016;1(6):637-638. doi:10.1001/jamacardio.2016.1207
Review

Updates on Acute Coronary Syndrome: A Review

Abstract Full Text
has active quiz
JAMA Cardiol. 2016;1(6):718-730. doi:10.1001/jamacardio.2016.2049

In this narrative review, Eugene Braunwald and colleagues summarize recent advances in understanding the pathophysiology, diagnosis, treatment, and prognosis of patients with acute coronary syndrome.

From the JAMA Network

Predicting Risk of Ischemic or Bleeding Events After Percutaneous Coronary Intervention

Abstract Full Text
JAMA Cardiol. 2016;1(6):731-732. doi:10.1001/jamacardio.2016.2190

This commentary discusses a study published in JAMA describing the accuracy of a decision rule for predicting benefits and risks of continuing dual antiplatelet therapy >1 year after PCI.

JAMA Cardiology Clinical Challenge

A 71-Year-Old Man With Complicated Myocardial Infarction

Abstract Full Text
JAMA Cardiol. 2016;1(6):735-736. doi:10.1001/jamacardio.2016.1263

A 71-year-old man with nonischemic cardiomyopathy and an LVEF <20% developed ST elevation in leads v4-6 after successful PCI for right coronary artery occlusion. What would you do next?

JAMA Cardiology Clinical Guidelines Synopsis

Focused Update on Duration of Dual Antiplatelet Therapy for Patients With Coronary Artery Disease

Abstract Full Text
JAMA Cardiol. 2016;1(6):733-734. doi:10.1001/jamacardio.2016.2171

This Clinical Guideline Synopsis summarizes a 2016 ACC/AHA focused guideline update on duration of dual antiplatelet therapy in patients with coronary artery disease.

Editor's Note

Exploring the Potential Benefits and Risks of Anticoagulation for Atrial Fibrillation During Hospitalization for Sepsis

Abstract Full Text
free access
JAMA Cardiol. 2016;1(6):690-691. doi:10.1001/jamacardio.2016.2193
JAMA Cardiology Masthead

JAMA Cardiology

Abstract Full Text
free access
JAMA Cardiol. 2016;1(6):626. doi:10.1001/jamacardio.2015.0033
×